Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Maurizio Colecchia
Observed name:
M. Colecchia
Institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele,
Fondazione IRCCS Istituto Nazionale dei Tumori,
IRCCS San Raffaele Roma
Observed institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele,
Fondazione IRCCS Istituto Nazionale dei Tumori,
IRCCS San Raffaele Roma
ORCID:
0000-0003-1914-0743
Observed ORCID:
0000-0003-1914-0743
OpenAlex ID:
A5022125828
Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial
2026
·
Andrea Necchi
, Joep J. de Jong
, et al.
·
Journal of Clinical Oncology
·
4
PDF
Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel
2024
·
Valentina Tateo
, Antonio Cigliola
, et al.
·
Clinical Genitourinary Cancer
·
4
275MO Neoadjuvant sacituzumab govitecan, followed by radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC): Updated interim results of SURE-01 trial
2024
·
B.A. Maiorano
, A. Cigliola
, et al.
·
Annals of Oncology
·
2
PDF
The evolution of prostate cancer grading: from Gleason score to risk taxonomy and the artificial intelligence revolution
2026
·
Enrico Munari
, Pietro Antonini
, et al.
·
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
·
1
Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy
2026
·
Chiara Mercinelli
, Giuseppe Basile
, et al.
·
Clinical Genitourinary Cancer
Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: Final results and biomarker analyses of the SURE-01 trial.
2026
·
Brigida Anna Maiorano
, Joep de Jong
, et al.
·
Journal of Clinical Oncology
Molecular characterization of residual disease post-neoadjuvant sacituzumab govitecan (SG), pembrolizumab, or their combination in patients with muscle-invasive bladder cancer (MIBC).
2026
·
Andrea Necchi
, Joep Jacobus de Jong
, et al.
·
Journal of Clinical Oncology
Association between non-luminal molecular subtypes and complete response rates after neoadjuvant chemo-immune therapy for muscle-invasive bladder cancer: Biomarker analyses of NURE-combo and BLASST-01 phase 2 clinical trials.
2026
·
Joep Jacobus de Jong
, Shilpa Gupta
, et al.
·
Journal of Clinical Oncology
PDF
Targeting residual bladder cancer disease for better treatment outcomes
2025
·
I. Locatelli
, C. Venegoni
, et al.
·
European Urology Open Science
First results of NURE-Combo: A phase 2 study of neoadjuvant Nivolumab (NIVO) and Nab-Paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with Muscle-Invasive Bladder Cancer (MIBC)
2024
·
C. Mercinelli
, G. Basile
, et al.
·
European Urology
OP20 Three year-survival outcomes after neoadjuvant pembrolizumab and radical cystectomy: Final results from the PURE-01 study
2022
·
T.C. De Padua
, G. Basile
, et al.
·
ESMO Open
596 Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration
2015
·
P. Giannatempo
, G.R. Pond
, et al.
·
European Urology Supplements
Show more works
View as search
Works count:
12
Citation count:
11
H-index:
2
I10-index:
Year
Topic
Type